ArticleEndocrine connections2025
Survival analysis between different treatment strategies of mixed adenoneuroendocrine carcinoma (MANEC): a population-based study.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mixed adenoneuroendocrine carcinoma (MANEC) is rare and heterogeneous. Currently, there is no concise treatment standard for MANEC. This study aimed to explore the prognostic impact of different treatment methods in MANEC. Methods: The surveillance, epidemiology and end results database was utilized to evaluate the outcomes of MANEC using propensity score matching (PSM) , stratified and site-specific survival analysis. Results: A total of 935 patients diagnosed with MANEC were enrolled in this study. Across most analyses, surgery performance (compared with no surgery) was associated with improved survival outcomes for MANEC patients, except for the site-specific analysis of small intestine, in which no significant association between surgery and patients' survival was found. Radiotherapy exhibited no significant association with patients' survival in most cases, and associated with poor prognosis of MANEC in certain specific analyses. Inconsistent effects of chemotherapy on MANEC were observed. Positive impact of chemotherapy on MANEC was indicated in PSM for chemotherapy or radiotherapy. Contradictory effects of chemotherapy were suggested based on the stage of MANEC, with unfavorable outcomes in early-stage and favorable outcomes in advanced-stage. The impact of chemotherapy on survival was influenced by the administration of surgery or radiotherapy. Site-specific analyses indicated that chemotherapy was beneficial to MANEC of the hepatic-biliary-pancreatic system. Conclusions: The results of this study demonstrate the variable impact of different treatment strategies for MANEC. Surgery was generally associated with improved survival outcomes, while radiotherapy did not show a beneficial effect on MANEC. The effects of chemotherapy on MANEC were inconsistent in specific analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.